Treatment of stress urinary incontinence in women

Evaluation of autologous muscle derived stem cells and fibroblasts injection into the women’s paraurethral tissues for the treatment of stress urinary incontinence.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140911019125N7

Enrollment

Registered

2020-05-02

Start date

2017-02-19

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinences in women. Stress incontinence (female) (male)

Interventions

Intervention group: The sample taken from the patient is brought to the laboratory. The sample is then digested enzymatically and cultured. After the cells reach a sufficient confluency, 40 million ce

Eligibility

Sex/Gender

Female

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Women aged between 40 to 65 years old Stress Urinary Incontinence symptoms Urodynamic stress incontinence confirmed by multichannel urodynamic testing Positive cough stress test Patients desire to surgical correction of stress urinary incontinence inadequate response to conservative treatment of SUI

Exclusion criteria

Exclusion criteria: History of surgery on external genitalia, bladder neck, bladder or urethra Desire to future childbearing History of bleeding or current anti-coagulation therapy Current genitourinary fistula or urethral diverticulum Active urinary infection Uncontrolled Diabetes

Design outcomes

Primary

Measure	Time frame
Closure pressure. Timepoint: Before intervention and 1,3,6,12 months after intervention. Method of measurement: Urodynamic test.;Urinary flow rate. Timepoint: Before intervention and 1,3,6 and 12 months after intervention. Method of measurement: Urodynamic test.;Maximum detrusor pressure during voiding. Timepoint: Before intervention and 1,3,6,12 months after intervention. Method of measurement: Urodynamic test.;Amount of urine left. Timepoint: Before intervention and 1,3,6,12 months after intervention. Method of measurement: Urodynamic test.;Severity of urinary symptoms. Timepoint: Before intervention and 1,3,6,12 months after intervention. Method of measurement: questionnaire.	—

Measure

Time frame

Closure pressure. Timepoint: Before intervention and 1,3,6,12 months after intervention. Method of measurement: Urodynamic test.;Urinary flow rate. Timepoint: Before intervention and 1,3,6 and 12 months after intervention. Method of measurement: Urodynamic test.;Maximum detrusor pressure during voiding. Timepoint: Before intervention and 1,3,6,12 months after intervention. Method of measurement: Urodynamic test.;Amount of urine left. Timepoint: Before intervention and 1,3,6,12 months after intervention. Method of measurement: Urodynamic test.;Severity of urinary symptoms. Timepoint: Before intervention and 1,3,6,12 months after intervention. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Farsinejad

Kerman University of Medical Sciences

afarsinejad@kmu.ac.ir+98 34 3132 5374

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026